MAXIMUS, Inc. (MMS) Expected to Announce Quarterly Sales of $630.23 Million

Analysts forecast that MAXIMUS, Inc. (NYSE:MMS) will report $630.23 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for MAXIMUS’s earnings. The highest sales estimate is $635.60 million and the lowest is $623.28 million. MAXIMUS posted sales of $607.56 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 3.7%. The business is expected to report its next quarterly earnings report on Thursday, February 8th.

According to Zacks, analysts expect that MAXIMUS will report full year sales of $630.23 million for the current financial year, with estimates ranging from $2.51 billion to $2.53 billion. For the next year, analysts anticipate that the firm will post sales of $2.66 billion per share, with estimates ranging from $2.62 billion to $2.74 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for MAXIMUS.

MAXIMUS (NYSE:MMS) last posted its earnings results on Thursday, November 9th. The health services provider reported $0.81 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.04. MAXIMUS had a net margin of 8.54% and a return on equity of 23.97%.

A number of brokerages recently weighed in on MMS. Zacks Investment Research upgraded shares of MAXIMUS from a “hold” rating to a “buy” rating and set a $73.00 price target for the company in a research note on Wednesday, October 4th. Canaccord Genuity reiterated a “buy” rating on shares of MAXIMUS in a research note on Wednesday, December 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $65.60.

Shares of MAXIMUS (MMS) opened at $70.09 on Monday. The firm has a market cap of $4,565.42, a price-to-earnings ratio of 22.04, a P/E/G ratio of 2.63 and a beta of 1.34. MAXIMUS has a 52 week low of $51.74 and a 52 week high of $72.71.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 28th. Investors of record on Thursday, February 15th will be paid a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend is Wednesday, February 14th. MAXIMUS’s dividend payout ratio is currently 5.66%.

In other news, General Counsel David Francis sold 3,900 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.97, for a total value of $249,483.00. Following the completion of the sale, the general counsel now owns 15,090 shares in the company, valued at approximately $965,307.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Andrekovich sold 5,594 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $67.23, for a total transaction of $376,084.62. Following the completion of the sale, the insider now owns 27,996 shares of the company’s stock, valued at approximately $1,882,171.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,417 shares of company stock valued at $4,902,785. 3.10% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in MMS. Steward Partners Investment Advisory LLC purchased a new position in shares of MAXIMUS in the 4th quarter valued at about $169,000. Intl Fcstone Inc. purchased a new position in shares of MAXIMUS in the 2nd quarter valued at about $201,000. OLD National Bancorp IN purchased a new position in shares of MAXIMUS in the 3rd quarter valued at about $246,000. Cubist Systematic Strategies LLC increased its holdings in shares of MAXIMUS by 16.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,969 shares of the health services provider’s stock valued at $249,000 after purchasing an additional 546 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new position in shares of MAXIMUS in the 3rd quarter valued at about $269,000. Institutional investors own 94.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/22/maximus-inc-mms-expected-to-announce-quarterly-sales-of-630-23-million.html.

MAXIMUS Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on MAXIMUS (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply